AnPac Bio-Medical Science Co., Ltd. (ANPC) has filed a preliminary prospectus for a $27M IPO of American Depositary Shares (ADSs) priced $12 – 14. Each ADS represents one Class A ordinary share.
The Shanghai-based biotech develops blood tests for the detection and screening of cancer based on its cancer differentiation analysis (CDA) technology and device.
2019 Financials (9 mo.): Revenues: $1.1M (+29%); Net Loss: ($8.2M) (-78%); Loss/share: ($0.94) (-77%); Cash Consumption: ($4.6M) (-44%).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.